At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy
In Brief
An observational study for Hepatitis C. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The major goal of this project is to identify the role of the immune responses in the emergence of protease inhibitor mutants during therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedJan 2012
Primary CompletionJul 2014
Study CompletionDec 2014
TodayJul 2026
First PostedJan 25, 2012
Enrollment StartJan 1, 2012
Primary CompletionJul 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.4 years ago